Study of Safety and Efficacy on New Peritoneal Dialysis Solutions

Sponsor

Iperboreal Pharma Srl (Industry)

Overall Status

Withdrawn

CT.gov ID

NCT00858182

Collaborator

(none)

Enrollment

Arms

44.1

Duration (Months)

Study Details

Study Description

Brief Summary

A major challenge of peritoneal dialysis (PD) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (UF) profile. Study hypothesis is to evaluate the possibility to formulate PD solutions containing xylitol and L-carnitine as osmotic agents to partially replace glucose.

Condition or Disease	Intervention/Treatment	Phase
End-Stage Renal Disease	Drug: PD solution for nocturnal exchanges Drug: PD solution for diurnal exchanges	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Evaluation of a New Peritoneal Dialysis Solutions Containing Glucose, Xylitol and L-carnitine Compared to Standard PD Solutions in End-stage Renal Disease (ESRD) Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)

Study Start Date :

May 1, 2009

Anticipated Primary Completion Date :

Oct 1, 2012

Anticipated Study Completion Date :

Jan 1, 2013

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Group A	Drug: PD solution for nocturnal exchanges Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
Experimental: Group B	Drug: PD solution for diurnal exchanges Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.

Arm

Intervention/Treatment

Experimental: Group A

Drug: PD solution for nocturnal exchanges

Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.

Experimental: Group B

Drug: PD solution for diurnal exchanges

Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.

Outcome Measures

Primary Outcome Measures

To assess ultrafiltration efficacy of PD solutions containing L-Carnitine and Xylitol [4 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age ≥18 years;
Diagnosis of ESRD treated for at least three month with CAPD, as stated by the medical staff of the center;
CAPD treatment with 2.27% of glucose solution for the nocturnal exchange;
Stable clinical condition within four weeks before screening period, certified by medical/surgical history, physical examination and laboratory exploration;
Hemoglobin level ≥9g/dL;
Residual diuresis ≤800mL;
Absence of acute peritonitis and/or peritoneal catheter infection (either exit site or subcutaneous tunnel) episodes within three months before selection;
Stable peritoneal permeability, as confirmed by a PET between 0.50 and 0.81 during previous three months and at day 0 of the screening period;
Total urea Kt/V >1.5 per week at a control during previous three months and at day 0 of the screening period and/or minimal total creatinine clearance of 45 liter/week at a control during previous three months and at day 0 of the screening period; 1- To understand and sign an informed consent form.

For patients who will be included in Group B, the following criteria must be fulfilled too:

Be treated with Extraneal (nocturnal exchange bag solution) for at least 1 month
Be treated with 2 or 3 diurnal exchange bag solutions (solution bags with 1.36% or 2.27% glucose) and one nocturnal exchange bag solution (Extraneal)

Exclusion Criteria:

History of alcohol or drug abuse in the last six months before selection for the study;
Androgen therapy in the last six months before selection;
Active infections;
History of congestive heart failure stage III and IV NYHA;
History of major cardiovascular events like stroke, acute myocardial infarction, coronary or other arterial revascularization procedures in the last three months before selection;
Clinically relevant cardiac arrhythmia;
Clinically relevant abnormalities of functional hepatic tests;
Therapy with L-carnitine or its derivatives in the last three months before selection;
Pregnancy, lactating women or female subjects of childbearing potential who do not use an effective method of contraception;
Presence of relevant chronic medical conditions that could suggest exclusion of patient from the study or could interfere with assessment of study parameters, especially if the life expectation is less then one year;
Participation in another clinical study within the past month;
Known or supposed allergic reactions to L-carnitine or xylitol.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Iperboreal Pharma Srl

Investigators

Study Director: Cristina Capusa, PhD, "Dr Carol Davila" University Hospital of Nephrology, Romania
Study Chair: Gabriel Mircescu, PhD, "Dr Carol Davila" University Hospital of Nephrology, Romania